Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Further info on bond covenants etc https://www.ipfin.co.uk/en/investors/consent-solicitation-for-bonds.html
These rates are the sign of the times it seems thanks to Covid
are positive given the situation and demonstrates Amigo and FCA are working cohesively to an agreed outcome
VREQ currently in place governing complaint handling - expires 30/10 so expect an update and possible extension
Bump this great post up from ShiftingShares
https://www.shiftingshares.com/what-is-a-rights-issue/
Very happy with my recent purchase
Buying opportunity created presumably by Miton taking some profit and selling into the rise
I really don’t think that’s the case, I agree the timing of the acquisition and placing is fortuitous however this would have been set in motion a long time ago and in fact it’s quite probable that the placing may actually have been at a slight premium as TTG was trading around 190 recently prior to the iAbra collaboration
iAbra appear to have been thrown into the spotlight as a result of their successful trials at Heathrow airport and the associated press . To be fair TTG announced their manufacturing agreement earlier this month and even on the most recent communication detailing the launch they confirmed that although they had received orders totalling £2m the potential £280m was subject to regulatory approval - with iAbra receiving so much press it looks as though TTG were forced to notify the market
I hold and am currently underwater, however, with or without iAbra I’m confident that my money will see a decent return, however, I’m naturally hoping that we do indeed see £280m + orders of Virolens as this revenue would make the most recent highs look very cheap
TTG is not a pure Covid play which is what makes it interesting
A few days of turbulence but with potential blue skies ahead
We continue to manage the wind down of our legacy business, focusing on rightsizing the operations to the lower volumes, generating positive cash flow and exploring options to realise value in our proprietary payments technology. This leaves our balance sheet robust and our strategic efforts focused on realising further value for shareholders via our holding in Clearpay."
Just a load of sound bites with no real context other than a die hard attempt by the FT journalist to discredit iAbra and their technology
TTG have communicated appropriately and are simply the manufacturing partner who have consistently stated that sales are subject to approvals however orders worth £2m have been placed to date with September/October delivery
?It’s the test protocol in the pilot study that is now under review as part of a move to a full in vivo study. The positive control (known outcome) did not behave as expected under the pilot test protocol